ArticleCurrent colorectal cancer reports2016
Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.
Article in Current colorectal cancer reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- An algorithm-based meta-analysis of genome- and proteome-wide data identifies a combination of potential plasma biomarkers for colorectal cancer.Scientific reports · 2019Pooled it
- Article
- Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.Genes · 2026Review
- ctDNA in the Management of Resectable & Advanced Colorectal Cancer: Current Status and Future Directions.OncoTargets and therapy · 2026Review
- Liquid biopsy in breast cancer: current biomarker platforms and clinical applications.Exploration of targeted anti-tumor therapy · 2026Review
- Application of circulating tumor DNA liquid biopsy in nasopharyngeal carcinoma: A case report and review of literature.World journal of clinical cases · 2025Article
- Shining the Path of Precision Diagnostic: Advancements in Photonic Sensors for Liquid Biopsy.Biosensors · 2025Review
- Heterogeneity in Cancer.Cancers · 2025Review
- Advances in Molecular Mechanisms and Therapeutic Strategies in Colorectal Cancer: A New Era of Precision Medicine.International journal of molecular sciences · 2025Article
- Circulating tumor cells: indicators of cancer progression, plasticity and utility for therapies.Pathology oncology research : POR · 2025Review
- Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.Cancers · 2024Review
- A panorama of colon cancer in the era of liquid biopsy.The journal of liquid biopsy · 2024Review
- Liquid biopsy for gastric cancer: Techniques, applications, and future directions.World journal of gastroenterology · 2024Review
- Review
- Utilization of Circulating Tumor Cells in the Management of Solid Tumors.Journal of personalized medicine · 2023Review
- Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.Molecular cancer · 2023Review
- Enhancing clinical potential of liquid biopsy through a multi-omic approach: A systematic review.Frontiers in genetics · 2023Review
- Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring.Oncology research · 2023Review
- Circulating tumor cells in colorectal cancer - a review of detection methods and clinical relevance.Contemporary oncology (Poznan, Poland) · 2023Review
- Single-Cell DNA Methylation Analysis in Cancer.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are emerging noninvasive multifunctional biomarkers in liquid biopsy allowing for early diagnosis, accurate prognosis, therapeutic target selection, spatiotemporal monitoring of metastasis, as well as monitoring response and resistance to treatment. CTCs and ctDNA are released from different tumor types at different stages and contribute complementary information for clinical decision. Although big strides have been taken in technology development for detection, isolation and characterization of CTCs and sensitive and specific detection of ctDNA, CTC-, and ctDNA-based liquid biopsies may not be widely adopted for routine cancer patient care until the suitability, accuracy, and reliability of these tests are validated and more standardized protocols are corroborated in large, independent, prospectively designed trials. This review covers CTC- and ctDNA-related technologies and their application in colorectal cancer. The promise of CTC-and ctDNA-based liquid biopsies is envisioned.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.